Literature DB >> 16426246

Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups.

D A Akkad1, P Jagiello, P Szyld, R Goedde, S Wieczorek, W L Gross, J T Epplen.   

Abstract

We analysed whether the single nucleotide polymorphism (SNP) rs3087456 in the promoter of the MHC class II transactivator (MHC2TA) gene is associated with manifestation of rheumatoid arthritis, multiple sclerosis, narcolepsy and Wegener granulomatosis. The recently reported association in a northern population of the MHC2TA variation with these autoimmune diseases is not evident in the German population.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16426246     DOI： 10.1111/j.1744-313X.2006.00568.x

Source DB:  PubMed          Journal:  Int J Immunogenet        ISSN： 1744-3121            Impact factor:   1.466


  15 in total

1.  MHC2TA is associated with rheumatoid arthritis in Japanese patients.

Authors:  Noriko Iikuni; Katsunori Ikari; Shigeki Momohara; Taisuke Tomatsu; Masako Hara; Hisashi Yamanaka; Hiroshi Okamoto; Naoyuki Kamatani
Journal:  Ann Rheum Dis       Date:  2006-11-07       Impact factor: 19.103

2.  Protective effect of A at position - 168 in the type III promoter of the MHCIITA gene in systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Hirotaka Kaneko; Chihiro Terai; Naoyuki Kamatani
Journal:  Ann Rheum Dis       Date:  2007-09       Impact factor: 19.103

3.  Role of the MHC2TA gene in autoimmune diseases.

Authors:  Alfonso Martínez; Marta Sánchez-Lopez; Jezabel Varadé; Ana Mas; M Carmen Martín; Virginia de Las Heras; Rafael Arroyo; Juan Luis Mendoza; Manuel Díaz-Rubio; Benjamín Fernández-Gutiérrez; Emilio G de la Concha; Elena Urcelay
Journal:  Ann Rheum Dis       Date:  2006-09-29       Impact factor: 19.103

4.  Association between the functional MHC2TA -168 A/G polymorphism and susceptibility to rheumatoid arthritis: a meta-analysis.

Authors:  Young Ho Lee; Sang-Cheol Bae
Journal:  Clin Rheumatol       Date:  2015-10-06       Impact factor: 2.980

5.  CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis.

Authors:  Paola G Bronson; Stacy Caillier; Patricia P Ramsay; Jacob L McCauley; Rebecca L Zuvich; Philip L De Jager; John D Rioux; Adrian J Ivinson; Alastair Compston; David A Hafler; Stephen J Sawcer; Margaret A Pericak-Vance; Jonathan L Haines; Stephen L Hauser; Jorge R Oksenberg; Lisa F Barcellos
Journal:  Hum Mol Genet       Date:  2010-03-08       Impact factor: 6.150

6.  MHC2TA and FCRL3 genes are not associated with rheumatoid arthritis in Mexican patients.

Authors:  J F Mendoza Rincón; A K Rodríguez Elias; J M Fragoso; G Vargas Alarcón; K Maldonado Murillo; M L Rivas Jiménez; R E Barbosa Cobos; S Jimenez Morales; G Lugo Zamudio; C Tovilla Zárate; J Ramírez Bello
Journal:  Rheumatol Int       Date:  2015-09-08       Impact factor: 2.631

7.  HLA-DRB1 genes and the expression dynamics of HLA CIITA determine the susceptibility to T2DM.

Authors:  Rathika Chinniah; Vandit Sevak; Sasiharan Pandi; Padma Malini Ravi; Murali Vijayan; Arun Kannan; Balakrishnan Karuppiah
Journal:  Immunogenetics       Date:  2021-03-22       Impact factor: 2.846

8.  Variability in the CIITA gene interacts with HLA in multiple sclerosis.

Authors:  A Gyllenberg; F Piehl; L Alfredsson; J Hillert; I L Bomfim; L Padyukov; M Orho-Melander; E Lindholm; M Landin-Olsson; Å Lernmark; T Olsson; I Kockum
Journal:  Genes Immun       Date:  2014-01-16       Impact factor: 2.676

Review 9.  The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls reveals no evidence for association.

Authors:  P G Bronson; L A Criswell; L F Barcellos
Journal:  Ann Rheum Dis       Date:  2007-09-17       Impact factor: 19.103

Review 10.  Regulation of major histocompatibility complex class II gene expression, genetic variation and disease.

Authors:  L Handunnetthi; S V Ramagopalan; G C Ebers; J C Knight
Journal:  Genes Immun       Date:  2009-11-05       Impact factor: 2.676
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.